gonadotropin-releasing hormone

(redirected from Luteinizing hormone releasing hormone)
Also found in: Medical.
Related to Luteinizing hormone releasing hormone: Luteinizing hormone releasing hormone agonist

go·nad·o·tro·pin-re·leas·ing hormone

 (gō-năd′ə-trō′pĭn-rĭ-lēs′ĭng, -trŏp′ĭn-)
n. Abbr. GnRH
A hormone produced by the hypothalamus that signals the anterior pituitary gland to begin secreting luteinizing hormone and follicle-stimulating hormone. Also called luteinizing hormone-releasing hormone.

go·nad·o·tro·pin-re·leas·ing hor·mone

n. hormona que estimula la secreción de gonadotropina.
References in periodicals archive ?
Effects of ethanol on rat hypothalamic luteinizing hormone releasing hormone.
Thyroid hormone Releasing Hormone (THRH), Luteinizing Hormone Releasing Hormone (LHRH), Corticotrophin Releasing Hormone (CRH) were normal ruling out involvement of hypothalamus.
The therapeutic equivalence between bilateral orchidectomy and luteinizing hormone releasing hormone (LHRH) analogs has been accepted for over 2 decades.
15 September 2011 - Canadian Aeterna Zentaris Inc (TSE:AEZ) reported on Wednesday encouraging final Phase II efficacy and safety results for its targeted cytotoxic luteinizing hormone releasing hormone (LHRH) analogue, AEZS-108, in advanced endometrial cancer.
Steroidal modulation of the regulatory neuropeptides: luteinizing hormone releasing hormone, neuropeptide Y and endogenous opioid peptides.
Abstract: The luteinizing hormone releasing hormone agonist leuprolide acetate is used commonly to manage reproductive problems in pet birds.
The drug is a membrane-disrupting peptide (tMDP) designed to "seek and destroy" cancer cells by targeting those with excessive luteinizing hormone releasing hormone (LHRH) receptors.
Characterization of cDNA for precursor of human luteinizing hormone releasing hormone.
Nyberg C, Hiney J, Minks J, Dees L Ethanol alters N-methyl-DL-aspartic acid-induced secretion of luteinizing hormone releasing hormone and the onset of puberty in the female rat.
Silmultaneous asministration of a luteinizing hormone releasing hormone agonis and diethlystilbestrol in the initial treatment of prostatic cancer.
3 pg/mL in castration studies evaluating luteinizing hormone releasing hormone (LHRH) agonist treatment in young males (Schmidt et al, Arch Gen Psychiatry, 2004; 61:997-1004) and in men with prostate cancer (Smith, MR, Clin Cancer Res.
5 mg is a new 6-month-formulation of a luteinizing hormone releasing hormone (LHRH) agonist for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer, developed by Debiopharm Group.

Full browser ?